Application of Microporous Polysaccharide Hemospheres (MPH)

Seroma

Microporous Polysaccharide Hemospheres (MPH)

Memorial Health University Medical Center

The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy

The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy: A Prospective Randomized Trial

Cancer-related Fatigue

Neutropenia, Malignant

PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle

Astragalus polysaccharides 500 mg

500 ml saline, 3 days via i.v. infusion per chemotherapy cycle

Placebo

Epirubicin plus Cyclophosphamide every 21 days

EC Chemotherapy

E-Da Cancer Hospital

Chang Gung Memorial Hospital, Kaohsiung Branch

Chang Gung Memorial Hospital, Lakeview Branch

Chang Gung Memorial Hospital, Taipei Branch

Chang Gung Memorial Hospital, Linkou Branch

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

PhytoHealth Corporation

Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.

Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.

HER2/Neu Positive

Recurrent Breast Carcinoma

Stage IV Breast Cancer

HER-2/neu Intracellular Domain Protein

Laboratory Biomarker Analysis

Pertuzumab

Polysaccharide-K

Trastuzumab

Fred Hutch/University of Washington Cancer Consortium

Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Evaluated using physical examination and clinical labs. Type and grade of toxicities noted during treatment will be summarized.

Augmentation of NK cell activity is defined by a 2-fold increase in NK cell IFN-gamma production and CD107a expression from baseline after 4 weeks of oral administration of polysaccharide-K.

University of Washington

National Cancer Institute (NCI)

Office of Cancer Complementary and Alternative Medicine

5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month

Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month

5 g/d placebo in 10 500-mg capsules for one month

Seaweed Associated Changes in Healthy Subjects

Ten 500-mg capsules to be taken orally each day for 1 month

Seaweed

Placebo2

University of South Carolina Cancer Research Center

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

SELDI-TOF-MS was used to measure urinary and serum protein changes

Urinary iodine concentration changes were used to indicate adherence to taking the seaweed supplement.

University of South Carolina

U.S. Army Medical Research and Development Command

The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle
Group 1 will receive EW02 for 15 consecutive days during the second cycle
will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle.

The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle
Group 2 will receive 15 consecutive days of Placebo
Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle

Breast Cancer

Chemotherapy

Neutropenia

Name: EW02
Dosage form: capsule.
Dose(s): 350mg per capsule, 2 capsule tid.
Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3.

EW02

Tri-Service General Hospital

A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy

A Phase I/II Double-Blind, Randomized, Placebo-Control Pilot Study to Evaluate the Safety and Pharmacodynamic Activities of EW02 in Reducing Neutropenia Caused by Breast Cancer Chemotherapy

polysaccharide/kanker payudara

The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy

Database tanaman obat terlengkap yang didukung oleh sains